Cargando…
The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation
BACKGROUND: Docetaxel based therapy is one of the first line chemotherapeutic agents for the treatment of metastatic castrate-resistant prostate cancer. However, one of the major obstacles in the treatment of these patients is docetaxel-resistance. Defining the mechanisms of resistance so as to info...
Autores principales: | Lundon, D. J., Boland, A., Prencipe, M., Hurley, G., O’Neill, A, Kay, E., Aherne, S. T., Doolan, P., Madden, S. F., Clynes, M., Morrissey, C., Fitzpatrick, J. M., Watson, R. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333466/ https://www.ncbi.nlm.nih.gov/pubmed/28249598 http://dx.doi.org/10.1186/s12885-017-3100-4 |
Ejemplares similares
-
Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines
por: O’Neill, Fiona, et al.
Publicado: (2012) -
A gene expression profile indicative of early stage HER2 targeted therapy response
por: O’Neill, Fiona, et al.
Publicado: (2013) -
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
por: O'Neill, Amanda J, et al.
Publicado: (2011) -
The role of epithelial–mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel‐resistant prostate cancer
por: Hanrahan, Karen, et al.
Publicado: (2017) -
Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes
por: Corcoran, Claire, et al.
Publicado: (2012)